Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Other Non Operating Income (2016 - 2025)

United Therapeutics' Other Non Operating Income history spans 17 years, with the latest figure at $47.2 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 1915.38% year-over-year to $47.2 million; the TTM value through Dec 2025 reached $48.9 million, up 743.1%, while the annual FY2025 figure was $48.9 million, 743.1% up from the prior year.
  • Other Non Operating Income for Q4 2025 was $47.2 million at United Therapeutics, up from $6.1 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $97.2 million in Q1 2021 and bottomed at -$51.8 million in Q2 2022.
  • The 5-year median for Other Non Operating Income is -$1.6 million (2023), against an average of $2.1 million.
  • The largest annual shift saw Other Non Operating Income tumbled 23400.0% in 2021 before it skyrocketed 1915.38% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$28.8 million in 2021, then surged by 81.6% to -$5.3 million in 2022, then soared by 88.68% to -$600000.0 in 2023, then tumbled by 333.33% to -$2.6 million in 2024, then surged by 1915.38% to $47.2 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Other Non Operating Income are $47.2 million (Q4 2025), $6.1 million (Q3 2025), and -$100000.0 (Q2 2025).